Literature DB >> 17512433

A pathologist's perspective on emerging genomic tests for breast cancer.

W Fraser Symmans1.   

Abstract

Emerging molecular tests for breast cancer indicate how future progress in diagnostic pathology might guide patient care. However, the challenge will be to bring the best results from this exciting research into clinical use as accurate and reliable standardized tests that integrate into the diagnostic work-up.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17512433     DOI： 10.1053/j.seminoncol.2007.03.016

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  3 in total

1.  Epidemiology of triple negative breast cancers.

Authors:  Gretchen L Gierach; Aileen Burke; William F Anderson
Journal:  Breast Dis       Date:  2010

2.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Authors:  Christos Hatzis; Lajos Pusztai; Vicente Valero; Daniel J Booser; Laura Esserman; Ana Lluch; Tatiana Vidaurre; Frankie Holmes; Eduardo Souchon; Hongkun Wang; Miguel Martin; José Cotrina; Henry Gomez; Rebekah Hubbard; J Ignacio Chacón; Jaime Ferrer-Lozano; Richard Dyer; Meredith Buxton; Yun Gong; Yun Wu; Nuhad Ibrahim; Eleni Andreopoulou; Naoto T Ueno; Kelly Hunt; Wei Yang; Arlene Nazario; Angela DeMichele; Joyce O'Shaughnessy; Gabriel N Hortobagyi; W Fraser Symmans
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

3.  Genomic index of sensitivity to endocrine therapy for breast cancer.

Authors:  W Fraser Symmans; Christos Hatzis; Christos Sotiriou; Fabrice Andre; Florentia Peintinger; Peter Regitnig; Guenter Daxenbichler; Christine Desmedt; Julien Domont; Christian Marth; Suzette Delaloge; Thomas Bauernhofer; Vicente Valero; Daniel J Booser; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.